Jack Wallace
Stock Analyst at Guggenheim
(3.14)
# 1,061
Out of 5,182 analysts
21
Total ratings
57.89%
Success rate
273.86%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $170.22 | +46.28% | 4 | Oct 1, 2024 | |
| WW WW International | Maintains: Buy | $12 → $6 | $10.91 | -45.00% | 3 | Aug 2, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $27.27 | -37.66% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $1.57 | +791.72% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $160.94 | +36.70% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $9.67 | +313.65% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $6.42 | +1,457.63% | 1 | Mar 15, 2023 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $170.22
Upside: +46.28%
WW International
Aug 2, 2024
Maintains: Buy
Price Target: $12 → $6
Current: $10.91
Upside: -45.00%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $27.27
Upside: -37.66%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $1.57
Upside: +791.72%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $160.94
Upside: +36.70%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $9.67
Upside: +313.65%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $6.42
Upside: +1,457.63%